This site is intended for healthcare professionals

Phase IIIb open-label study of Onpattro shows benefit in hereditary ATTR amyloidosis.- Alnylam Pharmaceuticals

Read time: 1 mins
Last updated:8th Jun 2021
Published:8th Jun 2021
Alnylam Pharmaceuticals announced positive results from a Phase IIIb open-label study conducted to evaluate the safety, efficacy and pharmacokinetics (PK) of Onpattro (patisiran) in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy progression after receiving an orthotopic liver transplant (OLT).
Condition: ATTR (hATTR) amyloidosis+ Polyneuropathy
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest